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Abstract
Background: An extensive outbreak of equine influenza occurred across multiple countries in South America during
2012. The epidemic was first reported in Chile then spread to Brazil, Uruguay and Argentina, where both vaccinated
and unvaccinated animals were affected. In Brazil, infections were widespread within 3months of the first reported
cases. Affected horses included animals vaccinated with outdated vaccine antigens, but also with the OIE-
recommended Florida clade 1 strain South Africa/4/03.
Methods: Equine influenza virus strains from infected horses were isolated in eggs, then a representative strain
was subjected to full genome sequencing using segment-specific primers with M13 tags. Phylogenetic analyses
of nucleotide sequences were completed using PhyML. Amino acid sequences of haemagglutinin and neuraminidase
were compared against those of vaccine strains and recent isolates from America and Uruguay, substitutions were
mapped onto 3D protein structures using PyMol. Antigenic analyses were completed by haemagglutination-inhibition
assay using post-infection ferret sera.
Results: Nucleotide sequences of the haemaglutinin (HA) and neuraminidase (NA) genes of Brazilian isolate
A/equine/Rio Grande do Sul/2012 were very similar to those of viruses belonging to Florida clade 1 and clustered with
contemporary isolates from the USA. Comparison of their amino acid sequences against the OIE-recommended Florida
clade 1 vaccine strain A/equine/South Africa/4/03 revealed five amino acid substitutions in HA and seven in NA. Changes
in HA included one within antigenic site A and one within the 220-loop of the sialic acid receptor binding site. However,
antigenic analysis by haemagglutination inhibition (HI) assay with ferret antisera raised against representatives of
European, Kentucky and Florida sublineages failed to indicate any obvious differences in antigenicity.
Conclusions: An extensive outbreak of equine influenza in South America during 2012 was caused by a virus
belonging to Florida clade 1, closely related to strains circulating in the USA in 2011. Despite reports of vaccine
breakdown with products containing the recommended strain South Africa/03, no evidence was found of significant
antigenic drift. Other factors may have contributed to the rapid spread of this virus, including poor control of horse
movement.
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Background
Equine influenza is one of the major infectious respiratory
diseases in equids worldwide. The causative agent, equine
influenza virus (EIV), is a highly contagious pathogen
endemic in most parts of the world. Like other influenza
A viruses, EIV has two surface glycoproteins, haemagglu-
tinin (HA) and neuraminidase (NA). HA plays an essential
role in virus entry by attaching to host cell sialic acid
receptors and promoting membrane fusion [1]; it is a
major target of neutralizing antibodies and is therefore an
important component of commercial vaccines. NA has si-
alidase activity and is thought to play a role in virus entry
as well as exit. Antibodies elicited against influenza NA
are also known to contribute to protection and have re-
cently been shown to block both sialidase activity and
virus adsorption [2], however their importance for im-
munity against EIV remains unclear.
Two influenza subtypes are known to infect horses,
H7N7 and H3N8. H7N7 equine influenza was first iso-
lated in Europe in 1956, followed by H3N8 in 1963 [3, 4].
The two subtypes co-circulated, with reassortment, until
the last isolation of H7N7 in the late 1970s [5, 6]. Follow-
ing its emergence in South America, most likely from an
avian source EIV H3N8 diverged phylogenetically into
American and Eurasian lineages [7, 8], with sufficient anti-
genic differences to warrant inclusion of both in vaccines.
Subsequently three sub-lineages named Kentucky, Florida
and South American (Argentinian) emerged within the
American lineage [9], and the Florida sublineage has fur-
ther diverged into distinct clades 1 and 2 [10, 11]. Cur-
rently, viruses from the Florida sub-lineage are prevalent
worldwide and inclusion of representatives of both clade 1
and clade 2 are recommended for vaccines [12]. Florida
clade 1 (FC1) viruses are considered endemic in North
America, but have caused major outbreaks in Australia,
Japan and South Africa [13–15]. There have also been
smaller outbreaks reported in Europe from 2007 to 2009
[16–18]. In Asia and Europe viruses from Florida clade 2
(FC2) predominate, causing significant outbreaks in
China, India and Mongolia in recent years and smaller
scale outbreaks in multiple countries of Europe [19–23].
Vaccination has been widely used for the control of
equine influenza and commercial vaccines have been
available for several decades. Despite this, horses immu-
nized with potent vaccines occasionally fail to provide
adequate protection. Vaccine breakdown can occur as a
consequence of antigenic drift in HA [24, 25], a well-
established phenomenon amongst mammalian influenza A
viruses. Cumulative mutations over time result in amino
acid substitutions in HA, allowing eventual immune es-
cape of emerging strains from the humoral protection
of the host, previously acquired against earlier strains
[26, 27]. Additionally, reassortment among gene seg-
ments during mixed infections of influenza viruses can
contribute to the appearance of new strains, a process
known to have occurred amongst recent EIV strains
from different sub-lineages [10, 11]. To counteract the
effects of antigenic drift, surveillance and vaccine strain
selection are carried out for EIV. In 2010 the World Or-
ganisation for Animal Health (Office International des
Epizooties, OIE) updated the recommendations for suit-
able antigens for commercial vaccines to include a repre-
sentative strain from both Florida clade 1 and Florida
clade 2. However, many vaccine manufacturers still pro-
vide products with outdated vaccine strains.
During 2012, an extensive outbreak of equine influenza
spread through South America, first reported in Chile in
December 2011 and affecting Brazil by February 2012. The
outbreak spread rapidly through Chile, Brazil, Uruguay
and Argentina [28, 29] but it is thought likely that other
countries in South America were also affected. Horses
carrying EIV were transported from Uruguay to Dubai,
highlighting the risk to other countries [23]. Prior to this
outbreak, the most recent Brazilian EIV strain to undergo
molecular characterisation was A/eq2/Brazil/1987 [30].
This paper describes the 2012 Brazilian outbreak and the
molecular and antigenic characterisation of a representa-
tive EIV isolate, A/equine/Rio Grande do Sul/2012.
Methods
Collection of samples
Nasopharyngeal swabs were collected from horses show-
ing typical influenza clinical signs, including nasal dis-
charge, cough and pyrexia. All sampled horses were aged
between 2 and 3 years old and only horses within the first
3 days of the onset of clinical signs were sampled. Clinical
samples were processed for diagnostic testing at Universi-
dade Estadual de Londrina, Brazil with viruses isolated in
fertile hen’s eggs and MDCK cells. Further analyses of
egg-grown virus isolates were completed at the Animal
Health Trust, UK.
EIV diagnosis: RNA detection from clinical samples
Purification of RNA from swab samples was performed
using guanidinium thiocyanate and silica particles [31]. For
detection of EIV RNA, a two step RT-PCR was employed
using equine-specific H3 HA primers [32]. Reverse tran-
scription (RT) was carried out using SuperScript III
Reverse Transcriptase (Life Technologies) according to
manufacturer’s recommendations at 55 °C. PCR ampli-
fication was performed using Platinum® Taq DNA Poly-
merase (Life Technologies).
Virus isolation
Virus isolation was attempted from RT-PCR positive
samples, simultaneously in embryonated hens’ eggs and
Madin-Darby canine kidney cells (MDCKs). For isolation
in eggs 0.1 ml of each swab sample was inoculated into
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the allantoic fluid of 11-day-old embryonated SPF eggs,
as described previously [10]. For isolation in MDCKs,
cells were cultured in 25 × 145 mm tubes and rotated.
Before inoculation, samples were pre-treated with 2 μg/
ml of TPCK-trypsin for 30 min at 37 °C and the cells
were washed three times with PBS containing 0.5 μg/ml
of TPCK-trypsin. After inoculation, the tubes were incu-
bated for 90 min on a roller at 33 °C. The inoculum was
discarded and cells washed with sterile PBS before adding
serum-free Earle’s medium containing antibiotics and
0.5 μg/ml of TPCK trypsin. After 72 h, tubes were frozen
at −80 °C. All samples were subjected to two passages in
eggs and cells under the conditions described above.
Genetic analyses
RNA was extracted from low passage egg-grown isolates
using a QIAamp Viral RNA Mini Kit (Qiagen) according
to manufacturer's instructions. Following RT with Super-
script II and the UNI-12 primer [33], PCR products suit-
able for sequence analysis were generated using gene
specific primers tagged with M13 primer sequences as
described previously [34]. Amplification products were vi-
sualized on 1 % agarose gels with GelRed nucleic acid
stain (Biotium) then purified using a QIAquick PCR puri-
fication kit (Qiagen) according to manufacturer’s direc-
tions. Sequencing was completed on an ABI PRISM® 3100
Genetic Analyzer (Applied Biosystem) using BigDye Ter-
minator v3.1 (Applied Biosystem). Nucleotide sequences
were edited using SeqMan II, version 5.03 (DNAstar Inc.)
and BioEdit (Ibis Pharmaceuticals Inc.). Alignments were
performed using ClustalW2 (EMBL-EBI) and Maximum-
Likelihood trees of nucleotide sequences for each segment
were constructed using PhyML version 3.
Antigenic characterization
Serum was raised against A/equine/Rio Grande do Sul/
2012 in two co-housed 6 month old female ferrets by intra-
nasal instillation of 0.1 ml of a limiting dilution egg-grown
stock of EIV per nostril, equivalent to a final dose of 2 × 106
EID50. Sera were collected 3 weeks post-infection and
stored at −20 °C. The remaining ferret antisera were from
AHT archives. Prior to use, antisera were treated with
potassium periodate, 3 % glycerol-PBS added and heat-
inactivated at 56 °C for 30 min. Haemagglutination inhib-
ition (HI) assays were carried out in V-bottomed 96-well
plates, as described previously [23]. HI titres were expressed
as the reciprocal of the highest dilution to show 100 %
inhibition of haemagglutination.
Ethical approval
Ferret sera were raised under a UK Home Office project
licence. All work underwent full ethical review at the
Animal Health Trust, by 3Rs and the Animal Welfare
and Ethical Review (AWERB) committees and complied
with the revised Animals (Scientific Procedures) Act
1986 under the EU Directive 2010/63/EU.
Results
Outbreak description
During 2012 equine influenza outbreaks were reported
throughout South America, including Chile, Brazil, Uruguay
and Argentina ([23, 28, 29]; this manuscript). Virus was
first isolated from horses in the state of Rio Grande do
Sul, in the extreme south of Brazil (Fig. 1). Clinical cases
of EIV were first reported in February, following an Inter-
national Creole Rodeo held in Vacaria. Shortly after the
event finished, further cases were reported in Porto Alegre
and races were cancelled due to the poor health status of
the horses. On 7th March, nasopharyngeal swabs were col-
lected from six Thoroughbred horses at the Jockey Club
of Porto Alegre. Within 24 h, influenza-like clinical signs
were reported further north at the Jockey Club of Soro-
caba, Sorocaba city, in the state of São Paulo (Fig. 1).
Horses presented with pyrexia ranging from 39 to 41 °C
and five Quarter Mile horses and one Thoroughbred were
sampled. Samples collected from both sites were positive
for EIV by RT-PCR.
In late March a barrel racing competition was held near
Sorocaba city, with approximately 1,200 Quarter Mile
horses participating from locations throughout Brazil. An-
ecdotal reports indicated that sick animals were present at
the event, later press reports indicated that equine influ-
enza had subsequently spread to the southeast, midwest-
ern and some northeastern states of Brazil. Press reports
from 10 and 26th April, 2012, stated that the disease had
spread to the states of Pernambuco, Paraiba and Rio
Grande do Norte after a competitive vaquejada event
(Fig. 1). On 15 May, 2012 in the Federal District, the
press reported that an ongoing exhibition event was
cancelled due to EIV infection. Around 100 rural prop-
erties had horses showing clinical signs and around 600
horses from local breeders were affected. The Jockey
Clubs of Sorocaba and Rio de Janeiro were not inter-
dicted. Sorocaba had the disease under control before
the arrival of the authorities and the Jockey Club of Rio
de Janeiro had prohibited the entry of other animals
from other jockey clubs, thus preventing the spread of
EIV into its facilities.
Diagnosis and virus isolation
EIV RNA was detected by RT-PCR directly from 8 of 12
nasopharyngeal swabs collected from two jockey clubs in
two different states. Four samples were positive from
Sorocaba and four from Porto Alegre. After two serial
passages, virus was successfully isolated from five samples
in embryonated eggs and three in MDCK cell culture. The
isolates originated from one horse with unknown vaccin-
ation history, two horses vaccinated with a vaccine
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containing the American strain A/equine/Kentucky/97
and two horses vaccinated with a vaccine containing the
Florida clade 1 strain A/equine/South Africa/4/03. The
antigen and adjuvant content of the vaccines cited here
are shown in Table 1. Initial isolation on MDCK cells did
not result in obvious cytopathic effect (CPE), however
after two further passages the virus isolates caused marked
cellular destruction (data not shown).
Vaccination history
Four out of the six sampled horses from Sorocaba had
been vaccinated with inactivated South Africa/4/03 antigen
and a fifth horse with inactivated Kentucky/97. One horse
had an unknown vaccination history. In Porto Alegre, four
horses had unknown vaccine history and two horses had
received a booster containing Kentucky/97. Of the vacci-
nated horses, only two had received a booster vaccination
during the previous 30 days; one had a dose of South
Africa/4/03- and the other a dose of Kentucky/97-
containing vaccine. Both horses had pyrexia at the time of
sampling (39 and 40 °C respectively). All the remaining
horses with known vaccination history had received their
last vaccination booster more than 4 months previously.
All the swabbed horses had been vaccinated, including
those where full details were not available.
Phylogenetic analysis of genes encoding surface
glycoproteins HA and NA
Virus was successfully isolated from two horses at Rio
Grande do Sul. The nucleotide sequences covering the
coding regions and the majority of the untranslated 5’
and 3’ ends were determined for all eight segments for
the isolate A/equine/Rio Grande do Sul/1/12 and sub-
mitted to GISAID [35]. For comparative purposes, the
whole genome was also determined for a recent clinical
isolate from the USA, A/equine/Kentucky/1/11. For
phylogenetic analysis, representative equine H3N8 HA
and NA nucleotide sequences from the Pre-divergence,
Table 1 Vaccine adjuvants and virus antigens of products used to vaccinate horses sampled in this study
H3N8 antigen H7N7 antigen Adjuvant
Kentucky/97 Lipid-based
Kentucky/94 & South Africa/4/03 Prague/56 Aluminium hydroxide
Newmarket/2/93 & South Africa/4/03 Prague/56 Aluminium hydroxide
Fig. 1 Map of Brazil showing the distance in kilometers between the extreme points of the country, and indicating the states where the outbreak
was reported in chronological order: March (1), April (2) and May (3)
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Fig. 2 (See legend on next page.)
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Eurasian and Kentucky lineages and sub-lineages, as
well as contemporary isolates of Florida clades 1 and 2
were retrieved from GenBank and GISAID. The ana-
lysis was completed for HA1 only, due to a lack of
availability of full-length sequences for HA. Maximum
Likelihood Phylogenetic trees for HA1 and NA are
shown in Figs. 3 & 4 respectively. Analysis of the nu-
cleotide sequence of HA1 showed six distinct clusters
corresponding to the Pre-divergent and Eurasian line-
ages, as well as the Argentinian, Kentucky and Florida
(clades 1 and 2) sub-lineages (Fig. 2). All the 2012 se-
quences from South America were located within the
Florida clade 1 group, including isolates from Uruguay via
Dubai [23], Argentina [29] and those from Brazil reported
here. They were most closely related to viruses isolated in
the USA during 2011–2012 (Fig. 2). The vaccine strain
Kentucky/97 was more closely related to very early Florida
viruses, prior to the subdivision into clades 1 and 2,
whereas South Africa/03 grouped with early representa-
tives of Florida clade 1, as expected (Fig. 2).
The phylogenetic tree for the complete NA sequences
also formed well defined clusters corresponding to equiva-
lent lineages and sub-lineages as those described for HA1
(Fig. 3). The exception was the absence of a clear subdiv-
ision for the Argentinian sub-lineage, due to a lack of
available sequence data for representative strains. Again,
the isolates from the Brazilian outbreak clustered with vi-
ruses belonging to the Florida clade 1 group, in particular
the USA isolates from 2011 to 2012. Unfortunately, data
was not available for the vaccine strain Kentucky/97 nor
the recent strain from Argentina (Argentina/E-2345-1/12).
Comparison of HA amino acid sequences
The derived amino acid sequences of HA for Rio Grande
do Sul/1/12 and contemporary isolates from USA, Uruguay,
Argentina and Dubai [23, 29] were compared to the Florida
clade 1 OIE-recommended strains Ohio/03 and South
Africa/4/03, shown in Fig. 4. Within HA1, five consist-
ent amino acid substitutions (G7D, R62K, D104N, A138S
and V223I) were present in all the recent Florida clade 1
isolates, including the sequences from South America. Of
these, A138S occurred within antigenic site A and
V223I occurred within the 220 loop of the receptor-
binding site. Argentina/E-2397-3/12 had the additional
substitution M70V however, in the absence of further
sequences it is unclear whether this was common to all
viruses circulating in Argentina during 2012. Two
further partial HA1 sequences from Brazil (São Paulo/
IB19/12, residues 260–373) and Chile (Colina/2/12, res-
idues 1–164), were retrieved from Genbank and in-
cluded in the alignment. The sequence from São Paulo
was identical to the other South American strains,
whereas the Chilean sequence contained two unique
substitutions, A78P and A144P. Both substitutions
occur within antigenic regions of H3, within sites E and
A respectively. Compared with the vaccine strain Kentucky/
97, Rio Grande do Sul/1/12 had 11 changes within the
HA1 region and one change in HA2. The amino acid sub-
stitutions A138S, N159B and V78A were located in anti-
genic sites A, B and E respectively, whereas the change
A272V occurred in the loop region close to antibody-
binding site C. Within the region encoding HA2, a consist-
ent substitution I527V was observed in the Rio Grande do
Sul/12 and Dubai/1/12 strains compared to South Africa/4/
03, also seen in the American sequences from 2011
and Kentucky/1/12. The HA2 region was not covered
by the Argentinian sequences. The locations of indi-
vidual mutations were mapped on the three dimen-
sional equine H3 HA structure, shown in Fig. 5, which
shows comparison of the outbreak strain against both
the OIE-recommended vaccine strain Ohio/03 and
Kentucky/97, both of which were in use during the
outbreak.
Comparison of NA amino acid sequences
The NA amino acid sequences of the isolate Rio Grande do
Sul/1/12, Kentucky/97 and Florida clade 1 isolates from
2011 to 2012 were aligned to the OIE recommended strains
Ohio/03 and South Africa/4/03, shown in Fig. 6. More
recent sequences from 2013 isolates were also included to
aid the comparison. Six substitutions were observed in all
the recent Florida clade 1 sequences when compared with
the OIE-recommended Florida clade 1 strains: I8M, V35A,
R260K, E271G, S337N and G416. The additional substitu-
tion N205S was present only in the sequences from Brazil
and Dubai, both related to the South American outbreak of
2012. The earlier vaccine strain Kentucky/97 showed 15
changes when compared to the OIE recommended strains,
and 17 changes in comparison to the isolate Rio Grande
do Sul/1/12. The South American isolates from 2012
were most similar to 2011 isolates from the USA, the
majority of recent American strains from 2012–2013
had three additional substitutions within NA: R252K,
(See figure on previous page.)
Fig. 2 Phylogenetic analysis of HA1 nucleotide sequences from South America, 2012. Maximum likelihood tree based on EIV strains isolated
between 1963 and 2012. Bootstrap values obtained after 100 replicates are shown at major nodes. Major lineages and sub-lineages are labeled by
bars on the right. The OIE recommended strains South Africa/4/03, Ohio/03 (Florida clade 1) and Richmond/1/07 (Florida clade 2) are in black
uppercase letters. The vaccine strain Kentucky/97 is shown in green, the Brazilian strain Rio Grande do Sul/1/12 in blue, Dubai/1/12 and Argentina/
E-2345-1/12 in red
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D258N and T434K. Taken together, these data suggest
that the EIV responsible for the 2012 outbreak in South
America may have originated in the USA in 2011.
The locations of individual mutations were mapped on
the three dimensional structure for avian N1 NA, the
closest to N8 that has been resolved as a tetramer (Fig. 7).
As for HA, comparison of the outbreak strain against
both the OIE-recommended vaccine strain Ohio/03
and Kentucky/97 is shown. Alignments between avian N1,
avian N8 and equine N8 sequences were generated to allow
determination of the correct numbering (data not shown).
Comparison of other viral components
The derived amino acid sequences from the six segments
encoding PB2, PB1, PA, PA-X, NP, M1, M2, NS1, NS2-NEP
and PA-X of Rio Grande do Sul/1/12 were aligned with
the corresponding amino acid sequences for the OIE-
recommended strain Ohio/03 and recent isolates Kentucky/
1/11 and Dubai/1/12, the observed amino acid changes in
the alignments are summarised in Table 2. All sequence files
were deposited with GISAID (Global Initiative on Sharing
All Influenza Data), accession numbers are provided in
supplementary data, Additional file 1: Table S1. Comparison
of sequences of Dubai/1/12 and Rio Grande do Sul/1/12
against Ohio/03 and Kentucky/1/11 indicated that the
recent Florida clade 1 strains had acquired non-
synonymous mutations in seven of the eight segments
compared to the OIE-recommended strain from 2003. No
amino acid changes were observed in the viral nucleo-
protein. The South American strains were very similar to
the 2011 USA isolate, with only two additional mutations:
PB2 M66V observed in Dubai/1/12 and PA-X K227R in
both Dubai/1/12 and Rio Grande do Sul/1/12.
Antigenic characterisation
Antigenic characterization of the Brazilian isolates was
carried out by haemagglutination-inhibition (HI) assay.
The reactivity of Rio Grande do Sul/1/12 (RGdS/1/12)
isolate against a panel of post-infection sera raised in fer-
rets was compared against reference strains (Table 3).
The highest titres for the Brazilian isolate were obtained
against the Florida clade 1 sera, at 724–1024 these were
similar to or higher than those for homologous antigens
Dorset/09 and South Africa/4/03. The Florida clade 2
antisera gave titres of 128 and 256, 2 to 4- fold lower
against the Brazilian isolates than to the homologous
Florida clade 2 antigens. As expected, the serum against
European representative Newmarket/2/93 reacted poorly
against RGdS/1/12, as did the Kentucky antiserum.
These showed low titres against RGdS/1/12 and the other
Florida clade 1 strains that were 8- to 10- fold lower than
those obtained against the homologous strains. The ferret
serum raised against the Brazilian strain recognized the
FC1 strains better than FC2, Kentucky or European strains.
HI assays thus confirmed that the isolates from Brazil were
antigenically related to viruses belonging to Florida clade 1,
as predicted from their HA sequences. The viruses tested
were recognised well by sera raised against the OIE-
recommended strain South Africa/4/03 and the serum
raised against the Brazilian strain recognised other FC1
strains, providing no evidence for significant antigenic drift.
Discussion
Large-scale epidemics of EIV have been reported since the
first transmission of H3N8 in horses in the early 1960s. In
some instances these have occurred in immunologically
naïve populations, such as the outbreak in South Africa in
2003 and that in Australia in 2007. Epidemics that also
affect vaccinated animals suggest that significant antigenic
drift away from vaccine strains may have occurred. In
2012, a Florida clade 1 EIV spread through several coun-
tries in South America, affecting both vaccinated and
unvaccinated animals. In some cases, animals were vacci-
nated with products that contained outdated strains that
did not comply with current OIE recommendations, it is
therefore not surprising that these animals showed clinical
signs. However, animals vaccinated with a whole inacti-
vated product containing an OIE-compliant Florida clade
1 virus were also affected. Although detailed vaccination
records were not available, this is an early indication that
the OIE recommendations for this sub-lineage may need
updating in the near future.
Antigenic mismatches have been a major variable
in well-documented vaccine breakdowns worldwide
[14, 36, 37]. In horses immunized with inactivated vac-
cines, there is a high correlation between the level of anti-
bodies against HA, determined by single radial haemolysis
assay, and the level of protection. However, this applies in
cases where the infecting EIV is homologous to the vac-
cine antigen [38]. When the infecting virus is antigenically
heterologous, the mismatch between the vaccine and the
virus can decrease the vaccine efficacy, and consequently
higher levels of circulating antibodies are needed in order
to neutralize the infection [39]. In such instances, vaccines
may continue to offer protection against clinical signs but
not necessarily reduce virus shedding and these animals
(See figure on previous page.)
Fig. 3 Phylogenetic analysis of NA nucleotide sequences from EIV. Maximum likelihood tree based on EIV strains isolated between 1963 and
2012. Bootstrap values obtained after 100 replicates are shown at major nodes. Major lineages and sub-lineages are shown by bars on the right.
The OIE recommended strains South Africa/4/03, Ohio/03 (Florida clade 1) and Richmond/1/07 (Florida clade 2) are in black uppercase letters.
Representative of the South American outbreak, Rio Grande do Sul/1/12 is shown in blue and Dubai/1/12 in red
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become a potential source of infection to susceptible
horses [40]. In the absence of serological data we can-
not rule out the possibility that vaccinated animals had
poor antibody titres, which may have played a part in
the outbreak.
Here we describe genetic and antigenic analysis, includ-
ing determination of the full genome sequence, for a
representative isolate of the outbreak in Brazil in 2012.
Comparison of HA and NA sequences indicated that
there were multiple substitutions between the glycopro-
teins of these viruses and the OIE-recommended strain
South Africa/4/03, however those in HA did not fulfil the
much-quoted requirement for ‘four or more changes
affecting two or more antigenic sites in HA1’. Nor were
there multiple changes in regions previously shown to be
important for EIV [37]. Substitutions of interest included
(See figure on previous page.)
Fig. 4 Comparison of HA amino acid sequences. Rio Grande do Sul/1/12 and 2011–12 Florida clade 1 strains from the USA were aligned to the
OIE-recommended vaccine strains Ohio/03 and South Africa/4/03 strains (top). Additional complete and partial sequences available from the
South American outbreak were also included for Dubai/1-3/12, Argentina/E-2397-3/12, Argentina/E-2345-1/12, Colina/2/12, São Paulo/IB19/12 and
Uruguay/E-1918-1/12. Kentucky/97, a vaccine strain used during the outbreak, is also shown. Amino acid identity is represented with a dot
Fig. 5 HA structure, showing location of amino acid substitutions between Rio Grande do Sul/1/12 and vaccine strains. The amino acid
sequence of the outbreak strain was compared against two vaccine strains, A/equine/South Africa/4/03 and A/equine/Kentucky/97. The locations of
the substitutions are indicated in red on the influenza H3 structure for A/equine/Richmond/1/07 (protein database number PDB: 4UO0, [44]). Structures
were examined using MacPyMOL and images collected for top and vertical views
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Fig. 6 NA amino acid alignment. Amino acid sequences for Rio Grande do Sul/1/12, and 2011–13 Florida clade 1 strains from the USA were
compared to the recommended OIE strain Ohio/03 (top). Amino acid identity is represented with a dot
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one within antigenic site A of H3 (A138S) and a change
within the 220 loop of the receptor-binding region
(I223V), which may alter avidity for sialic acid receptors.
The reciprocal substitution V223I has been observed in
some recent human H3N2 clinical isolates [41, 42]. None
of the amino acid changes observed here were unique to
the viruses circulating in South America and were typical
of those seen in USA isolates from 2011 onwards, which
did not cause large scale epidemics or reports of mass vac-
cine breakdown.
The results of antigenic analysis using a ferret antisera
panel supported the phylogenetic data, with the Brazilian
isolates showing good recognition by sera raised against
other members of Florida clade 1. The converse also
applied, with a ferret serum raised against Rio Grande do
Sul/1/12 reacting well against earlier members of the
Florida clade 1 sub-lineage. Recognition by sera against
Kentucky sublineage viruses was poor, similar to results for
earlier FC1 viruses [10, 23]. These data do not suggest that
there has been extensive antigenic drift away from the rec-
ommended OIE reference strain South Africa/4/03. Despite
this, vaccines containing the recommended strain South
Africa/4/03 did not perform as well as expected.
Several of the vaccines available in Brazil during 2012
contained outdated strains, including Kentucky/1/92,
Kentucky/94 and Kentucky/97. The antigenic analyses de-
scribed here indicated that high titres were only obtained
with sera from Florida clade 1 strains, not from sera against
the Kentucky sub-lineage. Vaccine breakdown with prod-
ucts containing these strains provide field data in support
of the decision by the OIE to recommend inclusion of both
Florida clade 1 and Florida clade 2 strains. More worryingly,
horses that had been vaccinated with South Africa/4/03
were also infected and showed clinical signs. This may have
been a consequence of antigenic mismatch with the Rio
Grande do Sul/2012 strain, although the HI using ferret
antisera had shown an efficient cross-reaction between both
strains. However, high levels of cross-reaction are not
necessarily correlated to cross-protection [36, 39]. Alterna-
tively, poor vaccine performance may have been due to a
lack of potency or poor adherence to vaccine manufac-
turer’s recommendations, rather than antigenic drift.
Fig. 7 NA structure, showing locations of amino acid substitutions between A/equine/Rio Grande do Sul/1/12 NA and Kentucky/97 (a, b) and
Ohio/03 (c, d). Top and bottom views are shown, with substitutions indicated in red using an N1 backbone, protein database number PDB: 2HTY
[45]. The residues are numbered according to the N8 sequence. The substitutions N205S, S359A, L371F, G424V (K/97), and N205S (Ohio/03) were
buried within the NA structure
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Table 2 Amino acid differences between recent Florida clade 1 isolates and Ohio/03
Gene PB2 PB1 PA PA-X M1 M2 NS1 NEP/NS2
aa position 63 66 212 398 660 667 684 686 731 94 200 584 621 644 59 259 348 354 409 465 59 227 240 15 59 76 87 66 209 52 64 86
Ohio/03 I M I I K V A V I F V R K V E P L T S I E K A V L Y E E N M K R
Kentucky/1/11 V . V V R I T I V L I Q R I K S I I N V K . D I M F D K I L R K
Dubai/1/12 V V V V R I T I V L I Q R I K S I I N V K R D I M F D K I L R K













Several other risk factors have been associated with influ-
enza infection of vaccinated horses during the last decade
[43]. In this instance, the use of aluminum hydroxide as an
adjuvant may be relevant, as seen in the UK outbreak of
2003 ([39], Table 1). Simple adjuvants such as this may
require a closer match between vaccine antigen and
outbreak strain in order to be effective than more complex
adjuvants that stimulate cell-mediated immunity [43].
The entry point for equine influenza into Brazil in
2012 is not known, nor has the precise origin of the
South American outbreak virus been determined. Based
on the reports cited here, after notification by Chile,
the outbreak spread quickly across the south of the
continent to Uruguay and Southern Brazil then further
north. Phylogenetic analysis of HA and NA here and HA1
sequences reported recently for Argentina and Uruguay
[29] showed that South American isolates from 2012 were
closely related to the 2011–12 isolates from the USA.
These data suggest that these viruses are likely to have
originated from the USA, but through possible import-
ation to Chile rather than gradual spread north to south.
Conclusions
The equine influenza epidemic in South America in 2012
was caused by a virus belonging to FC1, similar to those
circulating in the USA in the previous year. Phylogenetic
analysis indicated that strains from FC1 had acquired
several mutations in both HA and NA compared to the
OIE recommended strains from 2003, however antigenic
assessment using ferret antisera did not identify extensive
antigenic drift. In Brazil, the use of vaccine products
containing outdated strains may have contributed to the
outbreak, since most antigens available on the market
fell into this category. However, EIV was also isolated
from clinically affected horses vaccinated with an OIE
recommended strain. Poor control of horse movements
following competition events is likely to have contrib-
uted to the spread of EIV.
Consent for publication
Not applicable.
Availability of data and materials
All novel sequence data generated have been deposited
with the influenza virus sequence database, GISAID. Acces-
sion numbers are provided in Additional file 1: Table S1.
Additional file
Additional file 1: Table S1. GISAID EpiFlu database accession numbers
for EIV segments. (DOCX 43 kb)
Abbreviations
EIV: equine influenza virus; FC1: Florida clade 1; FC2: Florida clade 2;
GISAID: global initiative on sharing all influenza data; HA: haemagglutinin;
HI: haemagglutinin-inhibition; NA: neuraminidase; OIE: Office International des
Epizooties (World Organisation for Animal Health); RGdS: Rio Grande do Sul.
Competing interests
AW, AR and DE declare that they have no competing interests. EAB works
as a consultant for and LEdSF is employed by Laboratórios Vencofarma do
Brasil. Laboratórios Vencofarma did not provide financial support for these
genetic and antigenic studies, or have any influence in the conclusions of
this study
Authors’ contributions
This study is a result of collaborative work. DE, EAB, LEdSF, AFA and AAA
conceived this study and participated in its design. LEdSF collected field samples
from horses and provided data regarding the epidemic in Brazil. EAB, AW and
AR carried out the experimental work and sequence analysis. EAR, AW and DE
drafted the manuscript. AR participated in the discussion and modification of
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Dr Neil Bryant for valuable discussions and
critical review of the manuscript.
Funding
This work was supported by the Horserace Betting Levy Board ‘Equine
Influenza Program’ awarded to DE. EAB, AFA and AAA were funded by
Table 3 Antigenic analysis of Rio Grande do Sul/1/12 by HI assay
Ferret antisera New/2/93 New/1/93 Rich/1/07 Dev/11 SA/4/03 Dor/09 RGdS/1/12
Eur Ky FC2 FC2 FC1 FC1 FC1
Virus strain
Newmarket/2/93 512 64 128 64 <8 8 8
Newmarket/1/93 16 512 512 128 64 32 64
Richmond/1/07 32 128 512 256 128 256 128
Devon/11 128 256 1024 512 256 256 256
South Africa/4/03 32 16 128 128 1024 1024 1024
Dorset/09 32 16 128 64 1024 512 512
Rio Grande Do Sul/1/12 32 16 256 128 1024 1024 724
Representative post-infection ferret sera were used against European (Eur), American (Am) and Florida clades 1 and 2 (FC1 and FC2) lineages and sub-lineages
and Rio Grande do Sul/1/12
Homologous titres are shown in bold italics. New/1/93 - Newmarket/1/93, New/2/93 - Newmarket/2/93, Rich/1/07 - Richmond/1/07, Dev/11 - Devon/11, SA/4/03 -
South Africa/4/03, Dor/09 - Dorset/09, RGdS/1/12 - Rio Grande do Sul/1/12
Alves Beuttemmüller et al. Virology Journal  (2016) 13:45 Page 14 of 16
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and
Coordenação de Aperfeiçoamento Pessoal de Nível Superior (CAPES).
The funding bodies were not involved in the study design, collection of
samples, interpretation of data or preparation of the manuscript.
Author details
1Universidade Estadual de Londrina, Rodovia Celso Garcia Cid - Pr 445 Km
380, Campus Universitário, Londrina, Paraná CEP 86057-970, Brazil. 2Animal
Health Trust, Lanwades Park, Kentford, Suffolk CB8 7UU, UK. 3Laboratórios
Vencofarma do Brasil, Travessa Dalva de Oliveira, 237, Londrina, Paraná CEP
86030-370, Brazil.
Received: 22 December 2015 Accepted: 11 March 2016
References
1. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC. Structure of
the influenza virus haemagglutinin complexed with its receptor, sialic acid.
Nature. 1988;333:426–31.
2. Halbherr SJ, Ludersdorfer TH, Ricklin M, Locher S, Berger Rentsch M,
Summerfield A, Zimmer G. Biological and protective properties of immune
sera directed to influenza virus neuraminidase. J Virol. 2015;89:1550–63.
3. Sovinova O, Tumova B, Pouska F, Nemec J. Isolation of a virus causing
respiratory disease in horses. Acta Virol. 1958;2:52–61.
4. Waddell GH, Teigland MB, Sigel MM. A new influenza virus associated with
equine respiratory disease. J Am Vet Med Assoc. 1963;143:587–90.
5. Ito T, Kawaoka Y, Ohira M, Takakuwa H, Yasuda J, Kida H, Otsuki K. Replacement
of internal protein genes, with the exception of the matrix, in equine 1 viruses
by equine 2 influenza virus genes during evolution in nature. J Vet Med Sci.
1999;61:987–9.
6. Webster RG. Are equine 1 influenza viruses still present in horses? Equine
Vet J. 1993;25:537–8.
7. Worobey M, Han GZ, Rambaut A. A synchronized global sweep of the
internal genes of modern avian influenza virus. Nature. 2014;508:254–7.
8. Daly JM, Lai ACK, Binns MM, Chambers TM, Barrandeguy M, Mumford JA.
Antigenic and genetic evolution of equine H3N8 influenza A viruses.
J Gen Virol. 1996;77:661–71.
9. Lai ACK, Chambers TM, Holland Jr RE, Morley PS, Haines DM, Townsend
HGG, Barrandeguy M. Diverged evolution of recent equine-2 influenza
(H3N8) viruses in the Western Hemisphere. Arch Virol. 2001;146:1063–74.
10. Bryant NA, Rash AS, Russell CA, Ross J, Cooke A, Bowman S, MacRae S,
Lewis NS, Paillot R Zanoni R, Meier H, Griffiths LA, Daly JM, Tiwari A,
Chambers TM, Newton JR, Elton DM. Antigenic and genetic variations in
European and North American equine influenza virus strains (H3N8) isolated
from 2006 to 2007. Vet Microbiol. 2009;138:41–52.
11. Murcia PR, Wood JL, Holmes EC. Genome-scale evolution and
phylodynamics of equine H3N8 influenza A virus. J Virol. 2011;85:5312–22.
12. OIE. Equine influenza: OIE Expert Surveillance Panel on Equine Influenza Vaccine
Composition, OIE Headquarters, 4 March 2014. 2014. http://www.oie.int/our-
scientific-expertise/specific-information-and-recommendations/equine-influenza/.
13. Guthrie A. Equine influenza in South Africa, 2003 outbreak. In: Proceedings
of the 9th International Congress of World Equine Veterinary Association, 2006.
Marrakech, Morocco. www.ivis.org/proceedings/weva/2006/18.pdf.
14. Yamanaka T, Niwa H, Tsujimura K, Kondo T, Matsumura T. Epidemic of equine
influenza among vaccinated racehorses in Japan in 2007. J Vet Med Sci.
2008;70:623–5.
15. Cowled B, Ward MP, Hamilton S, Garner G. The equine influenza epidemic
in Australia: spatial and temporal descriptive analyses of a large propagating
epidemic. Prev Vet Med. 2009;92:60–70.
16. Bryant NA, Rash AS, Woodward AL, Medcalf E, Helwegen M, Wohlfender F,
Cruz F, Herrmann C, Borchers K, Tiwari A, Chambers TM, Newton JR,
Mumford JA, Elton DM. Isolation and characterisation of equine influenza
viruses (H3N8) from Europe and North America from 2008 to 2009. Vet
Microbiol. 2011;147:19–27.
17. Gildea S, Quinlivan M, Arkins S, Cullinane A. The molecular epidemiology of
equine influenza in Ireland from 2007–2010 and its international
significance. Equine Vet J. 2012;44:387–92.
18. Legrand LJ, Pitel PH, Marcillaud-Pitel CJ, Cullinane AA, Couroucé AM, Fortier
GD, Freymuth FL, Pronost SL. Surveillance of equine influenza viruses
through the RESPE network in France from November 2005 to October
2010. Equine Vet J. 2013;45:776–83.
19. Qi T, Guo W, Huang WQ, Li HM, Zhao LP, Dai LL, He N, Hao XF, Xiang WH.
Genetic evolution of equine influenza viruses isolated in China. Arch Virol.
2010;155:1425–32.
20. Virmani N, Bera BC, Singh BK, Shanmugasundaram K, Gulati BR, Barua S,
Vaid RK, Gupta AK, Singh RK. Equine influenza outbreak in India (2008–09):
virus isolation, sero-epidemiology and phylogenetic analysis of HA gene.
Vet Microbiol. 2010;143:224–37.
21. Gildea S, Fitzpatrick DA, Cullinane A. Epidemiological and virological
investigations of equine influenza outbreaks in Ireland (2010–2012).
Influenza Other Respir Viruses. 2013;7 Suppl 4:61–72.
22. Yondon M, Heil GL, Burks JP, Zayat B, Waltzek TB, Jamiyan BO, McKenzie PP,
Krueger WS, Friary JA, Gray GC. Isolation and characterization of H3N8
equine influenza A virus associated with the 2011 epizootic in Mongolia.
Influenza Other Respir Viruses. 2013;7:659–65.
23. Woodward AL, Rash AS, Blinman D, Bowman S, Chambers TM, Daly JM,
Damiani A, Joseph S, Lewis N, McCauley JW, Medcalf L, Mumford J, Newton
JR, Tiwari A, Bryant NA, Elton DM. Development of a surveillance scheme for
equine influenza in the UK and characterisation of viruses isolated in Europe,
Dubai and the USA from 2010–2012. Vet Microbiol. 2014;169:113–27.
24. Binns MM, Daly JM, Chirnside ED, Mumford JA, Wood JM, Richards CM,
Daniels RS. Genetic and antigenic analysis of an equine influenza H3 isolate
from the 1989 epidemic. Arch Virol. 1993;130:33–43.
25. Ito M, Nagai M, Hayakawa Y, Komae H, Murakami N, Yotsuya S, Asakura S,
Sakoda Y, Kida H. Genetic analyses of an H3N8 influenza virus isolate,
causative strain of the outbreak of equine influenza at the Kanazawa
Racecourse in Japan in 2007. J Vet Med Sci. 2008;70:899–906.
26. Laver WG, Air GM, Webster RG, Gerhard W, Ward CW, Dopheide TA.
Antigenic drift in type A influenza virus: sequence differences in the
hemagglutinin of Hong Kong (H3N2) variants selected with monoclonal
hybridoma antibodies. Virology. 1979;98:226–37.
27. Park AW, Daly JM, Lewis NS, Smith DJ, Wood JLN, Grenfell BT. Quantifying
the impact of immune escape on transmission dynamics of influenza.
Science. 2009;326:726–8.
28. WAHID. OIE World Animal Health Information System. http://www.oie.int/
wahis_2/public/wahid.php/Wahidhome/Home.
29. Perglione CO, Gildea S, Rimondi A, Miño S, Vissani A, Carossino M, Cullinane
A, Barrandeguy M. Epidemiological and virological findings during multiple
outbreaks of equine influenza in South America in 2012. Influenza Other
Respir Viruses. 2016;10:37–46.
30. Endo A, Pecoraro R, Sugita S, Nerome K. Evolutionary pattern of the H3
haemagglutinin of equine influenza viruses: multiple evolutionary lineages
and frozen replication. Arch Virol. 1992;123:73–87.
31. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der
Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin
Microbiol. 1990;28:495–503.
32. Borchers K, Daly J, Stiens G, Kreling K, Kreling I, Ludwig H. Characterisation
of three equine influenza A H3N8 viruses from Germany (2000 and 2002):
evidence for frozen evolution. Vet Microbiol. 2005;107:13–21.
33. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. Universal primer set for
the full-length amplification of all influenza A viruses. Arch Virol. 2001;146:
2275–89.
34. Rash A, Woodward A, Bryant N, McCauley J, Elton D. An efficient genome
sequencing method for equine influenza [H3N8] virus reveals a new
polymorphism in the PA-X protein. Virol J. 2014;11:159. doi:10.1186/1743-
422X-11-159.
35. GISAID EpiFlu database. Editorial: action stations: the time for sitting on flu
data is over. Nature. 2006;441:1028. http://platform.gisaid.org.
36. Newton JR, Daly JM, Spencer L, Mumford JA. Description of the outbreak of
equine influenza (H3N8) in the United Kingdom in 2003, during which
recently vaccinated horses in Newmarket developed respiratory disease.
Vet Rec. 2006;158:185–92.
37. Woodward A, Rash AS, Medcalf E, Bryant NA, Elton DM. Using epidemics
to map H3 equine influenza virus determinants of antigenicity. Virology.
2015;481:187–98.
38. Newton JR, Townsend HG, Wood JL, Sinclair R, Hannant D, Mumford JA.
Immunity to equine influenza: relationship of vaccine-induced antibody in
young Thoroughbred racehorses to protection against field infection with
influenza A/equine-2 viruses (H3N8). Equine Vet J. 2000;32:65–74.
39. Barquero N, Daly JM, Newton JR. Risk factors for influenza infection in
vaccinated racehorses: lessons from an outbreak in Newmarket, UK in 2003.
Vaccine. 2007;23:7520–9.
Alves Beuttemmüller et al. Virology Journal  (2016) 13:45 Page 15 of 16
40. Bryant NA, Paillot R, Rash AS, Medcalf E, Montesso F, Ross J, Watson J, Jeggo M,
Lewis NS, Newton JR, Elton DM. Comparison of two modern vaccines and
previous influenza infection against challenge with an equine influenza virus
from the Australian 2007 outbreak. Vet Res. 2010;41:19.
41. Haveri A, Ikonen N, Julkunen I, Kantele A, Anttila V, Ruotsalainen E, Nohynek H,
Lyytikainen O, Savolainen-Kopra C. Reduced cross-protection against influenza
A(H3N2) subgroup 3C.2a and 3C.3a viruses among Finnish healthcare workers
vaccinated with 2013/14 seasonal influenza vaccine. Euro Surveill.
2015;20:21028.
42. Tewawong N, Prachayangprecha S, Vichiwattana P, Korkong S, Klinfueng S,
Vongpunsawad S, Thongmee T, Theamboonlers A, Poovorawan Y.
Assessing antigenic drift of seasonal influenza A(H3N2) and A(H1N1) pdm09
viruses. PLoS One. 2015;10:e0139958. doi:10.1371/journal.pone.0139958.
43. Paillot R. A systematic review of recent advances in equine influenza
vaccination. Vaccines (Basel). 2014;2:797–831. doi:10.3390/vaccines2040797.
44. Collins PJ, Vachieri SG, Haire LF, Ogrodowicz RW, Martin SR, Walker PA,
Xiong X, Gamblin SJ, Skehel JJ. Recent evolution of equine influenza and
the origin of canine influenza. Proc Natl Acad Sci U S A. 2014;111:11175–80.
45. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ,
Gamblin SJ, Skehel JJ. The structure of H5N1 avian influenza neuraminidase
suggests new opportunities for drug design. Nature. 2006;443:45–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Alves Beuttemmüller et al. Virology Journal  (2016) 13:45 Page 16 of 16
